Business Description
Xilio Therapeutics is a clinical-stage biotech company focused on developing cancer treatments that activate specifically within tumors, aiming to improve effectiveness while reducing side effects for patients. Its leading drug candidates include XTX101, a targeted antibody therapy in Phase 2 trials for advanced solid tumors, alongside XTX202, another Phase 2 treatment, and XTX301, which is currently in earlier Phase 1 testing. Founded in 2016 and based in Waltham, Massachusetts, the company is working to build a pipeline of next-generation therapies that harness the body's immune system to fight cancer more precisely.
